Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children by Rodieux, F. (Frederique) et al.
REVIEW ARTICLE
Effect of Kidney Function on Drug Kinetics and Dosing
in Neonates, Infants, and Children
Frederique Rodieux1 • Melanie Wilbaux1 • Johannes N. van den Anker1,2,3 •
Marc Pfister1,4
Published online: 3 July 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Neonates, infants, and children differ from adults
in many aspects, not just in age, weight, and body composi-
tion. Growth, maturation and environmental factors affect
drug kinetics, response and dosing in pediatric patients.
Almost 80 % of drugs have not been studied in children, and
dosing of these drugs is derived from adult doses by adjusting
for body weight/size. As developmental and maturational
changes are complex processes, such simplified methods may
result in subtherapeutic effects or adverse events. Kidney
function is impaired during the first 2 years of life as a result of
normal growth and development. Reduced kidney function
during childhoodhas an impact not only on renal clearance but
also on absorption, distribution, metabolism and nonrenal
clearance of drugs. ‘Omics’-based technologies, such as
proteomics and metabolomics, can be leveraged to uncover
novel markers for kidney function during normal develop-
ment, acute kidney injury, and chronic diseases. Pharmaco-
metric modeling and simulation can be applied to simplify the
design of pediatric investigations, characterize the effects of
kidney function on drug exposure and response, and fine-tune
dosing in pediatric patients, especially in those with impaired
kidney function. One case study of amikacin dosing in neo-
nateswith reducedkidney function is presented.Collaborative
efforts between clinicians and scientists in academia, industry,
and regulatory agencies are required to evaluate new renal
biomarkers, collect and share prospective pharmacokinetic,
genetic and clinical data, build integrated pharmacometric
models for key drugs, optimize and standardize dosing
strategies, develop bedside decision tools, and enhance labels
of drugs utilized in neonates, infants, and children.
Key Points
Changes in kidney function during childhood modify
not only renal clearance but also absorption,
distribution, metabolism and nonrenal clearance of
drugs, affecting pharmacokinetics, response, and
dosing of drugs.
New renal biomarkers are needed. ‘Omics’-based
technologies, such as proteomics and metabolomics,
can be leveraged to uncover novel markers for
kidney function during normal development, acute
kidney injury, and chronic diseases.
Pharmacometric modeling and simulation can be
applied to simplify design of pediatric investigations,
characterize effects of kidney function on drug
exposure and response, and fine-tune dosing in
pediatric patients, especially in those with impaired
kidney function.
Collaborative efforts are required to evaluate new renal
biomarkers, optimize and standardize dosing strategies,
develop bedside decision tools, and enhance labels of
drugs utilized in neonates, infants, and children.
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1 Introduction
Administering drugs in neonates, infants, and children is
challenging. Up to 80 % of drugs prescribed in pediatric
patients have not been formally tested in this population,
and are therefore not labeled for use in neonates, infants,
and children (‘off-label use’) [1, 2]. Clinical research
involving children is more difficult than in adults for sev-
eral reasons [3–6]: (1) a small number of pediatric patients
are eligible for clinical trials; (2) the ethical hurdles of
conducting studies with placebo/control arms in sick chil-
dren; (3) cumbersome procedures for obtaining informed
consent and, if appropriate, informed assent; (4) lack of
suitable infrastructure to conduct pediatric clinical studies;
(5) limited market size, and thus economically less
attractive for pharmaceutical companies; and (6) technical
challenges of collecting laboratory, imaging, or clinical
data in pediatric patients.
A majority of drug dosing regimens for use in neonates,
infants, and children are derived from adult data by
adjusting for body weight/size. Such a simple extrapolation
from adults to pediatric individuals may not be appropriate.
Why? Children are not ‘small adults’. They differ from
adults in many aspects, not just in age and body weight: (1)
body composition changes in neonates, infants, and chil-
dren [7–9]; (2) organ maturation and development can
affect pharmacokinetics and response of drugs, especially
in children younger than 2 years of age [10, 11]; and (3)
therapeutic window (TW), also called therapeutic index
(i.e. exposure range with optimal efficacy/safety balance)
may change over time in children. As a result of organ
maturation and development, kidney function changes
during the first 2 years of life, which in turn will affect both
drug exposure and response in neonates and infants [12–
14].
Various factors can affect kidney function in neonates,
infants, and children: (1) development and maturation of
kidneys as described earlier [10]; (2) underlying kidney
diseases and comorbidities [15]; (3) medications and other
therapeutic interventions, such as hypothermia in neonates
[16–21]; and (4) environmental and genetic factors [22]
(Fig. 1).
The focus of this article is to (1) review physiological
differences between neonates, infants, children, and adults;
(2) review markers for assessing and monitoring kidney
function; (3) understand factors that affect kidney function
and its impact on drug exposure and response in pediatric
patients; (4) introduce quantitative approaches, such as
pharmacometric modeling and simulation, to simplify
designs of studies in pediatric patients, characterize effects
of the kidney on drug exposure and response, and fine-tune
dose strategies in pediatric patients, especially in those
with impaired kidney function; and (5) outline opportuni-
ties to facilitate development and optimize utilization of
therapeutics in neonates, infants, and children. The
majority of our examples and related discussion will focus
on neonates and young infants, who are particularly subject
to pharmacokinetic changes due to rapid growth, devel-
opment, and maturation of organs, including the kidneys.
Most studies using quantitative approaches such as phar-
macometric modeling and simulation are conducted in this
age range.
2 Method
Relevant articles in the PubMed and EMBASE databases
were identified using the following keywords: ‘neonates’,
‘infant’, ‘children’, ‘pediatric’, ‘drug development’,
‘pharmacokinetics’, ‘kidney function’, ‘modeling’, ‘simu-
lation’, ‘drug dosing’, and ‘pharmacometrics’. Our search
was limited to English-language studies published in peer-
reviewed journals. Additional publications were identified
from review articles.
3 Physiological Differences Between Adults
and Children
Neonates, infants, and children differ from adults in many
aspects, not just in age, body weight and composition:
capacity of drug-metabolizing enzymes and kidney func-
tion change due to organ maturation and development,
resulting in altered drug exposure and response, especially
in children younger than 2 years of age. Stages of growth
are illustrated in Fig. 2 [23].
3.1 How Does Body Size and Composition Change
in Neonates, Infants, and Children?
Neonates, infants, and children represent a heterogeneous
population with nonlinear growth in size and bodyweight
from less than 500 g to more than 100 kg. Most changes in
body composition take place during the first 2–3 years of
life. Body weight doubles within 5 months, and triples
within 1 year, while body length increases by 50 % during
the first year, and doubles within 4 years. Proportions of
body weight contributed by fat, protein, intracellular and
extracellular water significantly change during childhood.
Total body water (TBW) (i.e. the sum of intracellular and
extracellular water) constitutes 80 % of body weight in
preterm neonates and 75 % in term neonates. It decreases
to adult values at 4 months and remains relatively constant
from this age onwards [24] (Fig. 3).
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3.2 How Does Development and Maturation
of Organs Affect Drugs in Neonates, Infants,
and Children?
Changes due to development and maturation of organs can
affect various aspects of drug pharmacokinetics, especially
in neonates and infants. Potential key changes in absorp-
tion, distribution, metabolism, and elimination of drugs
during the first years of life are presented in Table 1 [10,
25–27].
Absorption is decreased in neonates and infants, and
increases progressively during childhood, mainly due to
altered gastric pH, gastric emptying, and intestinal transit
time [10, 28]. Colonization of the gastrointestinal tract by
bacteria varies with age, route of delivery (vaginal vs.
cesarean section), type of feeding, and concurrent drug
therapy. This process influences metabolism of bile salts
and drugs by intestinal cytochrome P450 (CYP) as well as
intestinal motility and absorption [29]. An adult pattern of
microbial products is established around 5–12 months of
age [30, 31].
Distribution is modified essentially due to changes in
body composition and protein-binding capacity. The
amount of TBW is higher in neonates and infants [7].
Kidney 
funcon 
Genec/ 
Environmental  
factors 
Maturaon/ 
Development 
Medicaon/ 
Treatments 
Disease/ 
Comorbidies 
Fig. 1 Factors affecting kidney
function in neonates, infants,
and children
Preterm neonates Infants 
(> 28 days to  
23 months) 
Adolescents 
(12 to 18 years) 
Children 
(2 to 11 years) 
Term neonates 
(0 to 28 days) 
Fig. 2 Stages of growth.
Modified from the National
Heart, Lung, and Blood Institute
[23]
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Although the percentage of TBW does not change con-
siderably after 1 year of age, there is continuous decrease
in extracellular water from infancy to young adulthood. It
should be noted that drug-binding capacity to plasma
proteins is decreased in neonates and infants, resulting in
an increased volume of distribution of water-soluble drugs
[32]. Other factors such as altered regional blood flow and
immaturity of the blood-brain barrier can also affect dis-
tribution of drugs in neonates, infants, and children.
Metabolism of many drugs is dependent on hepatic
blood flow and activity of drug-metabolizing enzymes and
transporters. Hepatic blood flow is reduced in neonates, and
increases with increasing cardiac output over time. Due to
ontogeny, the capacity of drug-metabolizing enzymes and
transporters changes in neonates and infants. Activity of
phase I enzymes is reduced in neonates [11], increases
progressively during the first 6 months of life, may exceed
adult rates for a few years, slows during adolescence, and
80 
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Fig. 3 Body composition and
growth. Adapted from Bechard
et al. [24]
Table 1 Effects on drug pharmacokinetics related to organ maturation and development in children
Neonate/infant Effect on drug pharmacokinetics
Absorption : Gastric pH Variable effect on rate and extent of absorption
: Gastric emptying
: GI transit time
; Gastric enzyme activity
; Bile salt ; Absorption of some drugs
Changes in intestinal flora : Absorption of some drugs
Skin permeability : Absorption of some drugs
Distribution : TBW
: ECW
; Body fat
; Muscle mass
: Apparent Vd for water-soluble drugs
; Apparent Vd for drugs that bind to muscle and/or fat
; Albumin levels
; a1-acid glycoprotein
; Fraction bound for drugs highly bound to albumin
; Fraction bound for drugs highly bound to a1-acid glycoprotein, resulting in an increased
apparent Vd and/or increased toxicity
Metabolism ; Oxidative enzyme activity (CYP)a
; Glucuronidation (UGT)a
; Drug metabolism, plasma clearance with : in apparent half-life in neonates and young
infants
: Plasma drug clearance and ; in half-life of specific drugs
Elimination ; Kidney function (filtration,
reabsorption, secretion)
; Clearance and accumulation of renally excreted drugs
GI gastrointestinal, TBW total body water, ECW extracellular water, Vd volume of distribution, UGT uridine diphosphate glucuronosyltrans-
ferase, CYP cytochrome P450, : indicates increase, ; indicates decrease
a Apparent increase in activity for selected drug-metabolizing enzymes in older children/adolescents
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approaches adult rates by late puberty [33]. Similar age-
dependent changes are observed for the phase II enzymes,
uridine diphosphate glucuronosyltransferase (UGT), sul-
fotransferase, glutathione-S-transferase (GST), and N-
acetyltransferase (NAT) [10]. It is important to realize that
different isoenzymes within a family of enzymes can
mature at different rates during the first years of life.
Elimination of a majority of drugs from the body occurs
primarily via the kidney. Nephrogenesis starts at weeks 5–6
of gestation and is completed around weeks 34–35 of
gestation. This process of nephrogenesis is followed by
postnatal changes in intrarenal blood flow, but kidney
function is still impaired compared with that of adults. This
is due to a combination of factors: (1) immature glomerular
filtration and tubular function; (2) reduced kidney perfu-
sion pressure; and (3) inadequate osmotic load to produce
full counter-current effects. Glomerular filtration rate
(GFR) increases rapidly in neonates because of a postnatal
drop in kidney vascular resistance and an increase in renal
blood flow. GFR continues to increase gradually,
approaching adult levels by 12 months of age (Fig. 4), then
exceeding adult rates during preschool years to finally
reach adult values at prepubertal age [10, 34–39]. A tran-
sient increase has been explained by some authors to be
based on a larger increase of kidney weight compared with
body weight in preschool-age children. This might be
explained by an augmented increase of glomerular and
tubular cell size and an increased number of capillaries [40,
41].
Other factors influencing developmental changes in
kidney excretion are prematurity, kidney/urologic fetal
malformations, and concomitant medications. Preterm
infants are particularly susceptible because of ongoing
nephrogenesis [42]. A twofold increase of vancomycin
clearance, a drug almost exclusively excreted by the kid-
ney, from week 24 of postmenstrual age (PMA) to week 34
is described [43]. Neonates born small for gestational age
(SGA) were found to have a 16 % reduction in drug
clearance compared with preterm neonates who are
appropriate for gestational age (AGA) [44]. Drugs such as
betamethasone or indomethacin have been shown to alter
the normal pattern of postnatal kidney maturation in pre-
term neonates [45].
3.3 What Do We Know About the Therapeutic
Window of Drugs in Pediatric Patients?
Developmental changes can modify pharmacokinetic pro-
files of drugs (e.g. increase high peak-to-trough ratios or
variability in exposure), which may impact the efficacy/
safety balance [46]. Developmental changes may also
directly impact drug response without modifying pharma-
cokinetic profiles in children [11, 47–50]. Changing
expression of receptors during the first years of life can
affect efficacy/safety response of drugs in children [51]. A
study of sotalol in the treatment of supraventricular
tachycardia showed that neonates exhibited a higher sen-
sitivity towards QTc interval prolongation compared with
older children (Fig. 5) [52]. Augmented response to war-
farin and cyclosporine in children [48, 49], increased sen-
sitivity to d-tubocurarine, an antagonist of nicotinic
neuromuscular acetylcholine receptors, in neonates and
infants compared with children, adolescents, and adults
[53], and different sensitivity to bronchodilators because of
a lack of smooth muscles in the airways in neonates [54]
are other examples that illustrate that developmental
changes can impact the TW of drugs in neonates, infants,
and children.
3.4 What Do We Know About Pharmacogenetics
in Pediatric Patients?
As in the adult population, polymorphism in drug-metab-
olizing enzymes, drug-transport systems, and drug targets
can be associated with clinically relevant differences in
drug disposition and/or efficacy/safety profile. Polymor-
phisms, also known as single nucleotide polymorphisms
(SNPs), are defined as genetic variations occurring in at
least 1 % of the population. An increasing number of
studies are being published that describe differences in
drug response as a result of individual genetic background,
but most of these reports include only adult individuals [55,
56]. A few studies have shown the impact of pharma-
cogenomics in pediatric patients and highlighted differ-
ences between children and adults [55, 57].
In children with kidney or heart transplants, expression
of CYP3A5 affects clearance, dose requirement, and
immunosuppressive effects of tacrolimus. Children
expressing CYP3A5 (those carrying the A nucleotide,
Fig. 4 Typical maturation of GFR as a function of PNA, expressed as
a percentage of adult GFR. Adapted from Goyal [41]. GFR
glomerular filtration rate, PNA postnatal age
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defined as the *1 allele) have a higher dose requirement
than non-expressers (those homozygous for the G nucleo-
tide, defined as the *3 allele) [58, 59]. In children with
asthma and the CYP3A4*22 allele, fluticasone treatment is
associated with better asthma control than in those with the
wild-type allele [60]. Pharmacogenetic effects on drug
exposure and response can also impact efficacy/safety
profiles of drugs in pediatric patients. Cisplatin ototoxicity
has been associated with variants in the GST gene family
[61, 62]. It is estimated that 10 % of the population have
heterozygous mutations in the thiopurine S-methyltrans-
ferase (TPMT) gene, leading to decreased levels of the
enzyme, while as many as 1 in 300 have homozygous
mutations with very low levels of function of the enzyme
[63]. SNPs in the TPMT gene are associated with an
increased risk of developing severe and life-threatening
TPMT-mediated myelotoxicity or hepatotoxicity in chil-
dren treated with conventional dose of thiopurines [63, 64].
SNPs in the TPMT gene are also associated with a risk of
developing severe, potentially life-threatening bone mar-
row toxicity when treated with conventional doses of
azathioprine or mercaptopurine [65]. Studies have found a
strong association between HLA-B*1502 and carba-
mazepine-induced severe cutaneous adverse reactions [66–
68]. In such cases, drug labels should include treatment
strategies based on pharmacogenetic factors; see example
labels for 6-mercaptopurine [69], azathioprine (TPMT
variants) [70], and carbamazepine (HLA-B*1502 allele)
[71, 72]. Atomoxetine and pimozide are drugs with specific
genotype-based dose recommendations for children [56,
73]. Other examples of dose recommendations can be
found on the PharmGKB website (http://www.pharmgkb.
org).
Pediatric patients present unique pharmacogenetic
challenges as neonates, infants, and children have the
additional complexity of ontological phenotypes that
impact their responses to drugs. Thus, the role and
involvement of pharmacogenetics may differ between adult
and pediatric patients, and dosing strategies developed in
adults may be inaccurate in neonates, infants, and/or chil-
dren. An example is the role of CYP2C9 and VKORC1
genetic variations in warfarin treatment [74]. In adult
patients, such genetic variations are key contributors to
intersubject variability in warfarin exposure, whereas in
pediatric patients, age and body size have a more pro-
nounced impact on intersubject variability in warfarin
exposure than genetic variations [57, 74, 75].
4 Kidney Function and its Impact on Drugs
in Pediatric Patients
This section reviews (1) factors that can alter kidney
function; (2) effects of impaired kidney function on drug
exposure (pharmacokinetics) and response; and (3) mea-
sures for assessing and monitoring kidney function and
markers for detecting kidney injury/disease in pediatric
patients.
4.1 Which Factors Affect Kidney Function
in Pediatric Patients?
In neonates, infants, and children, multiple factors affect
kidney function: (1) development and maturation of the
kidneys as described earlier [10]; (2) acute kidney injury
(AKI), underlying kidney diseases and comorbidities [15];
(3) medications, renal replacement therapy (RRT) and
other therapeutic interventions, such as hypothermia in
neonates [16–19, 76, 77]; and (4) environmental and
genetic factors [22].
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4.1.1 Chronic Kidney Disease (CKD)
Although CKD is seen less frequently in pediatric patients
than in adult patients, it is not a rare disease as the overall
prevalence is 75 cases per million children [78]. In adults,
diabetic nephropathy and hypertension are the main causes
of CKD, whereas in pediatric patients, congenital disease
and glomerular disorders are frequent causes of CKD [79–
81].
4.1.2 AKI
In ‘developed countries’ the most prevalent causes of an
AKI associated with abrupt decrease in kidney function
include sepsis, congenital heart disease, and renal ischemia
[79, 82, 83]. Prospective studies report AKI incidence rates
of 4.5 and 2.5 % in children admitted to intensive care
units [82, 83]. In ‘less developed countries’, acute tubular
necrosis secondary to gastroenteritis and primary kidney
diseases such as hemolytic uremic syndrome and acute
glomerulonephritis are more likely involved. Neonates,
especially preterm newborns, are susceptible to acquiring a
kidney disease due to immature function of their kidneys,
rapid hemodynamic changes at birth, and increased risk of
hypovolemia as a result of insensible water losses and
exposure to nephrotoxic drugs [84].
4.1.3 Medications/Treatments
Nonsteroidal anti-inflammatory drugs (NSAIDs) [85–88],
aminoglycosides (gentamicin, amikacin, tobramycin,
netilmicin) [89–97] and glycopeptide antibiotics (van-
comycin, teicoplanin) [98–101], amphotericin B [102,
103], antiviral agents [104, 105], angiotensin-converting
enzyme (ACE) inhibitors [106, 107], calcineurin inhibitors
[108], radiocontrast media [109], and cytostatic drugs
[110–114] can be nephrotoxic and cause AKI in neonates,
infants, and children [17, 115]. Direct pathophysiological
mechanisms of nephrotoxicity include constriction of
intrarenal vessels, acute tubular necrosis, acute interstitial
nephritis, and, more infrequently, tubular obstruction [17].
Drugs without nephrotoxic effect may increase exposure to
potentially nephrotoxic agents by exhibiting drug–drug
interactions and altering drug-metabolizing enzymes or
transporters.
RRT is a particular case of ‘acquired’ changes in the
clearance of drugs. The use of RRT associated with AKI and
CKD was 15 per million children in the US in 2008 [116].
Drugs can be removed during RRT by diffusion (he-
modialysis) or convection (hemofiltration). Molecular
weight and size, protein binding, volume of distribution and
electrostatic charge are key characteristics affecting drug
dialyzability [117–119]. Drugs with high protein binding
([80 %), lipophilic drugs, cationic drugs (retained by
anionic protein charges in blood), and drugs with high
molecular weight are poorly dialyzable [117, 118, 120–124].
4.1.4 Genetic Factors
The influence of variants in genes encoding for receptors,
for example angiotensin II receptor 1 or toll-like receptor 9
(TLR-9), and peptides, for example vasopressin, involved
in the pathogenesis of kidney disease have been discussed
[22, 125–129]. Polymorphisms of genes encoding for
proteins involved in drug elimination could predispose to
drug nephrotoxicity. An association between ABCB1
polymorphisms, encoding for the P-glycoprotein (P-gp),
and tacrolimus-associated nephrotoxicity in pediatric
patients following liver transplant is reported, suggesting
that genotyping to find such polymorphisms may have the
potential to individualize tacrolimus therapy and enhance
drug safety [130]. SNPs in the genes encoding for CYP3A
enzymes and the nicotinamide adenine dinucleotide phos-
phate–CYP oxidoreductase (POR), a protein that functions
as an electron donor for CYP monooxygenase enzymes
[131], have been shown to influence tacrolimus dose
requirements. Individuals carrying the CYP3A4*22
T-variant allele have a lower tacrolimus dose requirement
than individuals with the CYP3A4*22 CC genotype, and
this effect appears to be independent of CYP3A5 genotype
status [132–134]. Individuals carrying the POR*28
T-variant allele have a higher tacrolimus dose requirement
than POR*28 CC homozygotes in CYP3A5-expressing
individuals [135–137]. Their influence on the risk of
nephrotoxicity is still inconsistent but they may also relate
to tacrolimus-induced chronic nephrotoxicity [138]. Fur-
thermore, the role of polymorphism in the organic cation
transporter 2 (OCT 2) gene to cisplatin-induced nephro-
toxicity has been reported [139].
4.2 How Does Impaired Kidney Function Impact
Drug Pharmacokinetics and Response
in Pediatric Patients?
Impaired kidney function affects not only renal clearance
but also absorption, distribution, metabolism, and nonrenal
clearance of drugs (Table 2) [122, 140–147].
Modification of distribution due to edema and decreased
protein-binding capacity may be especially significant in
children treated with highly hydrophilic drugs (such as
aminoglycosides). An already large TBW compartment
inherent of being a young child combined with a higher
TBW due to kidney disease could result in a severe
increased volume of distribution. The problem is often
underestimated and may therefore go undetected. Even if a
decrease in protein capacity induces an increase of the free
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fraction, the total drug concentration stays within the
acceptable therapeutic range.
4.3 How to Assess Kidney Function and Detect
Kidney Injury/Disease in Pediatric Patients?
Exact determination of kidney function is problematic in
children. Measurement of GFR markers, such as inulin,
iohexol, 51Cr-EDTA or 99mTc-diethylenetriaminepen-
taacetic acid is difficult in pediatric patients due to ethical
and practical reasons [158–161].
Equations based on serum creatinine measurements
have been developed to estimate GFR. In adults, the most
widely used equations for estimating GFR are the
Cockroft–Gault formula, the Modification of Diet in Renal
Disease (MDRD), and the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI). These equations tend
to overestimate GFR in children and should not be used in
pediatric populations [162]. Several equations have been
developed for pediatric patients: Schwartz, Counahan–
Barratt, Leger, the Bedside Chronic Kidney Disease in
Children (CkiD), Morris, Shull, Traub, Rudd, Dechaux,
Table 2 Impact of impaired kidney function on absorption, distribution, metabolism and excretion (ADME) of drugs
Pathophysiological
changes
Effects on drugs Impact
Absorption Formation of ammonia
in the presence of
gastric urease/buffers/
acid
Decreased absorption of drugs that are best
absorbed in an acidic environment, prolonged
gastric emptying, and delayed drug absorption
[145–147]
Increased variability in bioavailability in subjects
with kidney impairment compared with subjects
with normal kidney function
Increase in gastric pH Increased amounts of active drugs in systemic
circulation, higher bioavailability of acid-labile
compounds and reduced bioavailability of weak
acids [145–147]
Decrease in first-pass
hepatic metabolism
and biotransformation
Increased amount of drug removed during hepatic
first-pass as more unbound drugs are available at
the site of hepatic metabolism [145–147]
Bowel wall edema Decreased absorption [145, 147, 148]
Distribution Formation of edema and
ascites
Increases apparent volume of distribution of
highly water-soluble or protein-bound drugs
[145–147]
Lower plasma concentrations after a given dose
Decrease in albumin
concentration
Decreased affinity for drug reduces protein
binding in patients with uremia, substantially
increasing the unbound fraction of acidic drugs
[149]
More abundant drug available at the site of drug
action or toxicity
Metabolism Accumulation of uremic
toxins
Impaired glucuronidation to polar, water-soluble
metabolites due to decreased clearance of
glucuronide from plasma [150, 151]
Reduced removal of soluble metabolite
Altered intestinal, hepatic, and renal transporters,
intestinal P-gp, MRP-2 and OATP [143, 148,
152–154]
Accumulated active drug
Higher incidence of adverse drug
events
Altered hepatic and renal metabolic enzymes such
as CYP expression [148, 150, 151, 154–156]
The rate of reduction and hydrolysis reactions and
microsomal oxidation are reduced
Altered disposition of drugs metabolized by liver
through changes in plasma protein binding while
unbound intrinsic/metabolic clearance declines
with creatinine clearance [157]
Elimination Decrease in GFR Reduced clearance of drugs eliminated primarily
by glomerular filtration [141, 142, 144]
Increased plasma concentration and prolonged
half-life in drugs that are eliminated primarily
by glomerular filtration
Decrease in protein
binding
Decreased filtration of drugs, and this may result
in an increased amount secreted by renal tubules
[141, 142, 144, 157]
Prolonged excretion of drugs eliminated by active
organic ion transport systems in renal tubules in
patients with CKD; may become saturated upon
multiple drug administrations
P-gp P-glycoprotein, MRP-2 multidrug resistance protein 2, OATP organic anion-transporting polypeptide, CYP cytochrome P450, GFR
glomerular filtration rate, CKD chronic kidney disease
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Ghazali–Barratt and van den Anker formulas [163–170].
The most commonly used equations in children are the
Schwartz formula, Leger, CkiD, and Counahan–Barrat
formulas. The Schwartz formula, the most extensively
validated formula, is based on serum creatinine and was
first validated with data from 186 children, then with data
from 2192 children in 14 subsequent validation studies.
The Schwartz and Leger equations appear to overestimate
GFR in children with decreasing kidney function when
compared with measured inulin clearance [171–174]. The
CKiD and Counahan–Barrat equations have been devel-
oped in children with a median GFR of 40–45 ml/min/
1.73 m2, and tend to underestimate kidney function in
children with a GFR[60 ml/min [175]. It should be noted
that serum creatinine is influenced by muscle mass, gender,
diet, and tubular secretion. In children, serum creatinine
may also be affected by diseases such as neuromuscular
disease and anorexia nervosa [176]. At birth, the serum
creatinine values measured in the neonate reflect maternal
serum creatinine values because the placenta allows free
transfer of creatinine between the mother and her unborn
infant. Primarily in preterm infants the serum creatinine
values increase during the first days of life, reaching a peak
concentration around 5–7 days after birth before a gradual
decrease in values are seen [177–179]. The highest values
are seen in the most premature infants [180, 181]. As
already shown in the rabbit kidney model, this increase in
serum creatinine values is caused by an increased tubular
reabsorption of creatinine in these preterm infants [182,
183]. Therefore, serum creatinine is a poor marker for GFR
in neonates as it does not fulfill the assumptions of a purely
filtered substance from which to calculate GFR. This
underlines the need for, and evaluation of, newer, earlier
markers for kidney function.
Serum creatinine can be measured with different ana-
lytical methods: alkaline picrate method, Jaffe method
classic and compensated, and an enzymatic method trace-
able to isotope dilution mass spectrometry (IDMS) [184,
185]. Interlaboratory variation is high with some of these
methods [186, 187]; studies have reported median method
group variation coefficients of 6.4 % at a concentration of
80 lml/L [188]. Variation in serum creatinine values lead
to variation in derived calculations of kidney function.
Discrepancies are more pronounced in children aged
1–5 years [189]. Standardization initiatives have been
launched to reduce interlaboratory variation in creatinine
assay calibration [190].
In order to compensate for inaccuracy of existing
equations based on serum creatinine, alternative equations
utilizing cystatin C have been developed. Cystatin C is a
nonglycosylated protein produced in cells, not influenced
by gender, body habitus, or composition (Table 3) [191–
195].
Cystatin C does not cross the placental barrier and no
correlation was found between maternal and neonatal
serum cystatin [196]. Its reference value obtained in chil-
dren aged 4–19 years is 0.75 ± 0.09 mg/L [197]; cystatin
C levels are higher at birth (up to 4.2 mg/L) [191], and
decrease in neonates [196] and infants over time [193].
Cystatin C has not been shown to be superior to calculation
of GFR through the Schwartz formula in neonates [198].
Data on cystatin C in children receiving RRT are scarce
[199–202].
‘Omics’-based technologies, such as proteomics and
metabolomics, are uncovering new markers for kidney
injury/disease [203–212]. Neutrophil gelatinase-associated
lipocalin (NGAL) and kidney injury molecule-1 (KIM-1)
are promising candidates to detect kidney injuries in the
early stages. These proteins are expressed by renal tubules,
and clinical investigations have shown that they are mas-
sively expressed in cases of AKI in both adults and chil-
dren [203, 205, 207, 208, 213–217]. NGAL concentrations
seem to correlate with the severity/stage of CKD [204].
The ability to measure these newer markers noninvasively
in urine represents an advantage over current serum
markers, especially in children. Other new biomarkers are
evaluated for (1) AKI: interleukin (IL)-18, liver-type fatty
acid-binding protein (L-FABP), urinary insulin-like growth
factor-binding protein 7 (IGFBP7), and tissue inhibitor of
metalloproteinases-2 (TIMP-2) [206, 218–222]; (2) CKD:
b-trace protein (BTP), L-FABP, and asymmetric
dimethylarginine (ADMA) [223–227]; and (3) nephrotox-
icity: N-acetyl-glucosaminidase (NAG), GST, gamma-
glutamyl transpeptidase (GGT), alanine aminopeptidase
(AAP), and lactate dehydrogenase (LDH) [228–231].
Animal studies have shown modifications of the meta-
bolome in plasma and kidney tissues in renal ischemia/
reperfusion injury. Increase in prostaglandins, higher
catabolism of tryptophan and accumulation of citrulline in
the kidney could be metabolic signatures of intrarenal
inflammation associated with ischemia/reperfusion injury
[209]. Clinical studies in neonates, infants, and older
children are warranted to (1) evaluate potential measures
Table 3 Comparison between the kidney markers serum creatinine
and cystatin C
Characteristics Creatinine Cystatin C
Excretion by kidney Yes No
Reabsorption/secretion by renal tubules Yes No
Level affected by GA Yes No
Level affected by muscle mass Yes No
Level affected by gender Yes No
Influence from maternal plasma level Yes No
GA gestational age
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for kidney function, especially during the first days of life;
(2) test new markers such as NGAL and KIM-1 [232]; and
(3) explore ‘omics’-based methods in order to improve
detection and management of kidney injury/disease in
neonates, infants, and children [233].
5 Quantitative Approaches and Opportunities
in Pediatric Patients with Impaired Kidney
Function
This section introduces quantitative approaches, such as
pharmacometric modeling and simulation, to (1) simplify
designs of studies in pediatric patients; (2) characterize
effects of the kidney on drug exposure/response; (3) fine-
tune dosing in pediatric patients with impaired kidney
function; and (4) facilitate development and optimize uti-
lization of therapeutics in neonates, infants, and children.
5.1 What is Pharmacometrics?
Pharmacometrics is an emerging science of developing and
applying mathematical and statistical methods for charac-
terizing, understanding, and predicting a drug’s pharma-
cokinetics, and its effects on biomarker and clinical
responses over time [234, 235]. With pharmacometric
approaches, biological knowledge can be translated into
compartmental models with mathematical and statistical
components [236]. ‘Population approaches’, introduced by
Sheiner in the 1970s, can be utilized to quantify intersub-
ject variability, at the population level, and test covariate
effects on model parameters such as impact of body weight
or kidney function on drug clearance. Such population
models can also be applied to (1) project individual phar-
macokinetic, biomarker and clinical responses, e.g. by
Bayesian-inference [237–241]; (2) evaluate the impact of
alternative doses on pharmacokinetics, biomarker and
clinical responses; and (3) provide a scientific rationale for
individualized dosing strategies [242–245]. Quantitative
approaches such as pharmacometrics have been suggested
to quantify the impact of kidney function on drugs and the
impact of drugs on kidney function [246–248].
In pediatric patients, body weight reflecting growth, and
age describing maturation, are key covariates. As described
in Fig. 6, different age descriptors need to be considered in
pediatric patients, especially in neonates, including PMA,
gestational age (GA) and postnatal age (PNA), also called
chronological age [249].
Pharmacometric approaches include pharmacostatisti-
cal, exposure-response, and disease progression models
[236, 250, 251]. Systems pharmacology approaches may
represent more complex models, such as physiology-based
pharmacokinetic models (PBPK) consisting of a large
number of compartments to represent different organs or
tissues in the human body [235, 252]. PBPK models may
contain enzyme information from tissues, such as CYPs,
involved in the metabolism of drugs [253–255].
Both pharmacometrics and systems pharmacology have
been successfully applied in adults with impaired kidney
function to (1) evaluate and simplify sampling designs of
studies; (2) characterize and quantify the relationships
between kidney function and drug exposure or effect; (3)
fine-tune dosing strategies; and (4) enhance drug labels
leveraging model-based simulations [148, 256–259]. Such
quantitative approaches have the potential to facilitate
development and optimize utilization of drugs in neonates,
infants, and children, especially those with impaired kidney
function.
5.2 How to Simplify Sampling Designs of Studies
in Pediatric Patients?
Design and conduct of clinical studies in pediatric patients
are difficult due to enrollment constraints (especially
children \6 years of age), blood volume constraints
(especially in neonates and young infants), and other
practical challenges of collecting pharmacokinetic or other
samples [243, 260]. Pharmacometric and systems phar-
macology approaches, including PBPK-based simulations,
can be leveraged to (1) identify starting dose in first-in-
children pharmacokinetic studies and provide rationale for
dose regimen optimization; (2) simplify pharmacokinetic–
pharmacodynamic (PK–PD) sampling scheme (number and
timing of blood collections for pharmacokinetic and/or
PK–PD analyses); and (3) optimize sample size of studies
in neonates, infants, and children [243, 261–267].
Furthermore, PBPK models can also be applied in
neonates, infants, and children to (1) characterize phar-
macokinetic behavior of drugs; (2) identify genetic factors
that influence exposure/response of drugs; (3) assess risk of
drug–drug interactions; and (4) quantify the impact of
impaired kidney function on drugs [268–270]. PBPK
models validated in adults may be expanded to pediatric
patients by incorporating identified differences in drug
pharmacokinetics and response between children and
adults [267, 271].
Time
Post-menstrual age: PMA
Gestaonal age: GA Post-natal age: PNA
BirthFirst day of last 
menstrual period
Fig. 6 Age terminology during the perinatal period
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5.3 How to Characterize Drug Exposure–Response
and Enhance Drug Labels?
Pharmacometric and systems pharmacology approaches,
utilizing pharmacokinetic, biomarker and/or disease pro-
gression data, can be useful to (1) identify factors that
influence disease progression and responses to interven-
tions; (2) facilitate comparison of concentration–response
relationships across age groups; (3) link PD/biomarker
endpoints to (longer term) clinical outcome measures,
which may then be used as surrogate markers for assessing
efficacy in various age groups; (4) simulate treatment-re-
lated responses in pediatric patients with and without
impaired kidney function [259, 264, 272–274]; and (4)
enhance drug labels for pediatric patients, such as ataza-
navir [275], busulfan [276, 277], levofloxacin [278],
argatroban [279], piperacillin-tazobactam [280], etanercept
[281], and subcutaneous immunoglobulin [282–284].
5.4 How to Fine-Tune Dosing Strategies for Drugs
in Pediatric Patients with Impaired Kidney
Function?
In the absence of specific dosing recommendations for
children with changing kidney function, pediatric doses are
extrapolated from adult data [1]. A priori dosing (prior to any
measurement) in neonates, infants, and children is viewed as
a scaling exercise, assuming a simple linear relationship
between body weight and drug pharmacokinetics. Since
developmental and maturational processes in pediatric
subjects are mostly nonlinear, empirical dosing recom-
mendations may result in over- or underdosing, resulting in
toxicity or therapeutic failure. After initiating therapy, an
adjusted a posteriori dose, based on therapeutic drug moni-
toring (TDM), can be identified [285–289]. A limitation of
TDM in pediatric patients is that, for a majority of drugs,
target concentrations are derived from adult patients rather
than defined based on pediatric data, assuming similar
exposure/response and TW across age groups [290–294].
Pharmacometric approaches can be leveraged to identify
predictive covariates, characterize exposure/response and
TW of drugs, and provide a scientific basis for individual-
ized dosing strategies, including Bayesian-based TDM, in
neonates, infants, and children [242–245, 289, 295, 296].
Model-based approaches can also be applied to fine-tune
RRT strategies in pediatric patients [296–298].
5.5 What are the Opportunities to Facilitate
Development and Optimize Utilization of Drugs
in Pediatric Patients?
Strategic applications of pharmacometrics and systems
pharmacology have the potential to streamline develop-
ment and optimize utilization of drugs in pediatric patients
with and without impaired kidney function. An overview of
opportunities is provided in Table 4.
6 Case Study: How to Fine-Tune Amikacin Dosing
in Neonates with Impaired Kidney Function?
Neonates are known to be at high risk of infection and are
exposed to antibiotic-resistant bacterial pathogens; thus,
antibiotics are the class of medicines most frequently pre-
scribed in neonates. Early appropriate antimicrobial treat-
ment is imperative to optimize response and limit the
spread of resistance [300–302]. In addition, there is an
important lack of uniformity in dosing information to
ensure consistent drug exposure in neonates, leading to
inappropriate prescription of most antibiotics [303]. Phar-
macometric approaches can be used to (1) identify and
quantify covariate effects on pharmacokinetic parameters;
and (2) fine-tune dosing of antibiotics in neonates with and
without impaired kidney function.
In this section, we focus on the application of pharma-
cometrics to evaluate and fine-tune dose strategies of
amikacin in neonates. After penicillins, aminoglycosides
are the most commonly used drugs in the neonatal inten-
sive care unit [304]. Amikacin is used as a short-term
treatment of serious infections caused by strains of
Table 4 Quantitative approaches to enhance development and utilization of drugs in pediatric patients
Opportunity for pharmacometrics and systems pharmacology
Streamline development of therapeutics
for pediatric patients
Simplify design of PK–PD studies by performing model-based trial simulations [243, 261, 264]
Quantify impact of kidney function and RRT on drug exposure/response by applying
pharmacometric and PBPK models [259, 264, 272–274, 299]
Facilitate key development decisions by applying pharmacometric modeling and simulation [240,
264, 272–274]
Optimize utilization of therapeutics in
pediatric patients
Adjust/individualize dosing strategies by applying Bayesian-based TDM [243–245]
Provide scientific rationale for pediatric drug labels applying pharmacometric modeling and
simulation [281–284]
PK–PD pharmacokinetic–pharmacodynamic, RRT renal replacement therapy, PBPK physiology-based pharmacokinetic, TDM therapeutic drug
monitoring
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Pseudomonas sp., Escherichia coli, Klebsiella pneumo-
niae, Serratia sp., and Staphylococcus species [305–307].
This drug is almost exclusively eliminated by kidneys
(90 %) and its clearance reflects GFR [308]. There is huge
variability in the choice of neonatal dosing regimen used
across the world [309]. Leroux et al. found 19 different
neonatal dosing regimens proposed in the literature [44,
303, 310–323]. Amikacin use is difficult because of its
toxicity and pharmacokinetic variability, and no study or
specific recommendations in cases of changing kidney
function were described. Potential kidney effects on phar-
macokinetic parameters were tested by incorporating age
and weight as indirect measures for maturation and growth,
and serum creatinine as a measure of kidney function in a
population pharmacokinetic model [313, 324].
Sherwin et al. recently developed a population-based
pharmacokinetic model based on 70 pediatric burn patients
(6 months to 17 years) receiving amikacin, and found that
weighthad a significant influence on amikacin clearance [325].
De Cock et al. conducted a large population pharma-
cokinetic modeling study using data from 874 preterm and
term neonates treated with amikacin (range: GA 24–
43 weeks; PNA 1–30 days) [311]. Amikacin clearance was
found to be related to PNA and birth weight, with children
with higher age and weight having a faster maturation of
clearance. Furthermore, coadministration of ibuprofen
appeared to reduce amikacin clearance, likely (at least in
part) due to negative effect on kidney function [311, 326,
327]. The individual amikacin clearance can be predicted
using Eq. 1, with CLi being amikacin clearance in the ith
individual, CLp being the population value of amikacin
clearance, and bBW being birth body weight and PNA
corresponding to PNA:
CLi¼CLP bBW
bBWmedian
 1:34
 1þ 0:213 PNA
PNAmedian
  
0:838ibuprofen
ð1Þ
Figure 7 illustrates how the predicted clearance of
amikacin increases with birth body weight (representing
antenatal maturation) and PNA (representing postnatal
maturation), taking into account coadministration of
ibuprofen.
Predictive performance of this model was externally
validated in 239 neonates. An evidence-based dosing reg-
imen, summarized in Table 5, was proposed by performing
simulations with the developed model. They demonstrated
that the currently used dosing regimens for amikacin, based
on reference handbooks, may increase the risk of toxicities,
and should be revised [311].
The authors also performed a study to extrapolate the
amikacin model to other drug compounds almost entirely
eliminated through glomerular filtration and with similar
physicochemical properties (netilmicin, tobramycin, van-
comycin, and gentamicin). They showed that pediatric
covariate models may represent physiological information
on developmental changes in glomerular filtration that may
be leveraged to describe kinetics of other antibiotics that
are primarily eliminated by kidneys [328].
Fig. 7 Model-based predicted amikacin clearance values versus
bBW for PNA of 0, 14, or 28 days with and without coadministration
of ibuprofen, according to De Cock et al. [311]. bBW Birth body
weight, PNA postnatal age, CL clearance
Table 5 Amikacin dosing
regimen according to De Cock
et al. [311]. The dosing interval
is prolonged by 10 h when
ibuprofen is coadministered
Postnatal age (days) Current bodyweight (g) Dose (mg kg-1) Dosing interval (h)
\14 0–800 16 48
800–1200 16 42
1200–2000 15 36
2000–2800 13 30
C2800 12 24
C14 0–800 20 42
800–1200 20 36
1200–2000 19 30
2000–2800 18 24
C2800 17 20
1194 F. Rodieux et al.
7 Discussion and Outlook
Growth, maturation, and environmental factors affect drug
kinetics, response, and dosing in pediatric patients. Chan-
ges in kidney function, as a result of normal growth and
development as well as underlying kidney diseases,
comorbidities, medications, and environmental and genetic
factors, will not only have an impact on renal clearance but
also on the absorption, distribution, metabolism, and non-
renal clearance of drugs [141, 142]. Both drug exposure
and response may change during childhood and impact the
TW and efficacy/safety balance of drugs in neonates,
infants, and children. Current markers of kidney function
provide limited value in assessing and monitoring kidney
function in children, especially during the first days of life
and in cases of AKI [172, 173]. Therefore, new renal
biomarkers are needed. ‘Omics’-based technologies, such
as proteomics and metabolomics, can be leveraged to
uncover novel markers in plasma and urine for kidney
function during normal development, AKI, and CKD.
Motivated by challenges in conducting clinical studies
in pediatric subjects, supported by regulatory agencies such
as the European Medicines Agency (EMA) and the US
FDA, pharmacometric and systems pharmacology have
been suggested to facilitate the design and conduct of
studies in pediatric subjects [329]. Strategic use of model-
based quantitative approaches and biomarkers [240, 330]
has the potential to streamline development and optimize
utilization of drugs in pediatric patients with and without
impaired kidney function by (1) informing the design of
pediatric clinical trials, including sample size and first dose
selection, providing rationale for the dose range to be
studied, and simplifying PK–PD sampling; (2) character-
izing disease progression to project long-term clinical
outcomes; (3) quantifying the effects of impaired kidney
function (and RRT) on drug pharmacokinetics and/or
response; (4) facilitating key development decisions; and
(5) providing a scientific rationale for pediatric drug labels.
The recently formed Drug Disease Model Resources
(DDMoRe) consortium facilitates collaborations between
pharmaceutical industries and academic partners [331].
They aim to address the lack of common tools, languages,
and standards for modeling and simulation to improve
model-based knowledge integration. A public drug and
disease model library, supported by an open source and
universally applicable framework, provides access to dis-
ease modeling tools [331, 332]. It should also be noted that
online tools have been developed to facilitate evaluation and
optimization of study designs in adult and pediatric subjects.
For example, Mentre´ et al. developed a software tool known
as PFIM, which is a set of R functions that evaluates and/or
optimizes study designs based on the expression of the
Fisher information matrix (FIM) in nonlinear mixed effects
models (http://www.pfim.biostat.fr/) [333, 334].
In clinical practice, pharmacometric approaches can be
applied to identify predictive covariates, such as the impact
of kidney function changes on drugs, and provide a sci-
entific basis for optimizing dosing in pediatric patients
[242, 244, 245]. Bayesian-based TDM methods can
leverage patient characteristics, physiological differences
between adults and children, genetic and environmental
factors and pharmacokinetic properties of drugs, and
individualize dosing strategies in neonates, infants, and
children. Decision support tools are emerging to assist
clinicians at the bedside in personalized dosing of pediatric
patients, including neonates, such as the EzeCHiel (http://
www.ezechiel.ch/) [244, 289] and DoseMe software
packages (http://www.doseme.com.au/) [335].
Table 6 outlines opportunities to overcome challenges
in further streamlining development and optimizing
Table 6 Challenges and opportunities to facilitate development and optimize utilization of drugs in pediatric patients
Challenges in pediatric patients Opportunities for innovative and collaborative approaches
Lack of markers for assessing kidney function or
detecting AKI and CKD
Leverage proteomics and metabolomics to identify new renal markers for kidney
injury/disease
Lack of large pharmacokinetic, biomarker and clinical
outcomes datasets
Create and share integrated large databases
Lack of common tools, languages, and standards for
modeling and simulation
Develop platforms with standardized modeling tools
Lack of consensus, rationale on dosing strategies Collaborate between clinicians and scientists in academia and industry to optimize
and standardize dosing strategies
Lack of individualized dosing in children Apply model-based Bayesian TDM to leverage patient characteristics and fine-tune
personalized dosing
Lack of application of model-based approaches by
clinicians
Develop user-friendly bedside decision tools for clinicians
Lack of specific drug labels Collaborate between clinicians and scientists in academia, industry and regulatory
agencies to enhance drug labels
AKI acute kidney injury, CKD chronic kidney disease, TDM therapeutic drug monitoring
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utilization of therapeutics in neonates, infants, and chil-
dren, especially those with impaired kidney function.
Collaborative efforts between clinicians and scientists
in academia, industry, and regulatory agencies are
required to (1) identify new renal biomarkers for early
detection and enhanced monitoring of kidney injury and
disease; (2) collect and share prospective pharmacoki-
netic, genetic, and clinical data with the goal of creating
large clinical outcome databases; (3) build and evaluate
integrated pharmacometric models for key diseases and
therapeutics; (4) optimize and standardize dosing strate-
gies; (5) develop user-friendly bedside decision tools for
clinicians; and (6) enhance drug labels for neonates,
infants, and children.
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